Thorkell Gudjónsson

Thorkell Gudjónsson is an Assistant Professor at the Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen, where he leads research within the Sørensen Group. His work primarily focuses on genome stability mechanisms and their implications in cancer development.

Dr. Gudjónsson's research interests center on DNA damage response pathways, chromatin biology, and molecular mechanisms underlying cancer development. His work bridges basic molecular biology with translational cancer research, particularly in breast cancer and other malignancies. He investigates how genome maintenance pathways function under normal conditions and how their dysregulation contributes to carcinogenesis.

Analysis of his publication record reveals a consistent focus on DNA repair mechanisms and their relationship to cancer. His most recent work (2024-2025) has centered on tumor suppressors in breast cancer, replication stress disorders, and cytoskeletal proteins that maintain genome integrity. Earlier work established foundational knowledge about chromatin modifications during DNA damage response, with highly cited papers in Cell and Molecular Cell.

His research has generated significant scientific impact, with several papers accumulating hundreds of citations, particularly his 2012 Cell paper on TRIP12 and UBR5 which has received over 300 citations. His work appears in high-impact journals including Cell, Nature Communications, and The Journal of Clinical Investigation.

As a principal investigator within the Sørensen Group at BRIC, Dr. Gudjónsson collaborates extensively with researchers across multiple institutions, with particular strength in interdisciplinary cancer research combining molecular biology, genetics, and clinical medicine. His laboratory employs advanced techniques in molecular and cellular biology to investigate fundamental mechanisms of genome maintenance.